Navitoclax-piperazine
Navitoclax-piperazine (ABT-263-piperazine) is a Navitoclax analog and BCL-XL inhibitor. Navitoclax-piperazine is the ligand for target protein of PROTAC DT2216 (HY-130604). Navitodax-pperaie and E3 ubiquitin ligase VHL ligand can be used to synthesize PROTAC DT2216 (HY-130604).
Product Specifications
CAS Number
2143096-93-7
Product Name Alternative
ABT-263-piperazine
UNSPSC
12352005
Target
Bcl-2 Family; Ligands for Target Protein for PROTAC
Type
Reference compound
Related Pathways
Apoptosis; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/navitoclax-piperazine.html
Purity
99.73
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(NS(=O)(C1=CC=C(N[C@@H](CSC2=CC=CC=C2)CCN3CCNCC3)C(S(=O)(C(F)(F)F)=O)=C1)=O)C4=CC=C(N5CCN(CC6=C(C7=CC=C(Cl)C=C7)CCC(C)(C)C6)CC5)C=C4
Molecular Formula
C47H56ClF3N6O5S3
Molecular Weight
973.63
References & Citations
[1]Sajid Khan, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med 25, 1938–1947 (2019) .
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Bcl-xL
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
